# Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome

> **NCT07688161** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 106 (estimated)

## Conditions studied

- Diarrhea-predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** Trimebutine Maleate Tablets
- **DRUG:** Jingfang Granules

## Key facts

- **NCT ID:** NCT07688161
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-01
- **Final completion:** 2028-02
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688161, "Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*